| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2104 | 2003 |
| Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1686 | 2016 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1489 | 2018 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1488 | 2006 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1160 | 2008 |
| Survival of persons with and without HIV infection in Denmark, 1995–2005 N Lohse, ABE Hansen, G Pedersen, G Kronborg, J Gerstoft, HT Sørensen, ... Annals of internal medicine 146 (2), 87-95, 2007 | 1046 | 2007 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1021 | 2019 |
| A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus TN Kledal, MM Rosenkilde, F Coulin, G Simmons, AH Johnsen, S Alouani, ... Science 277 (5332), 1656-1659, 1997 | 606 | 1997 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 558 | 2014 |
| Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study M Helleberg, S Afzal, G Kronborg, CS Larsen, G Pedersen, C Pedersen, ... Clinical Infectious Diseases 56 (5), 727-734, 2013 | 521 | 2013 |
| Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin P Garred, HO Madsen, U Balslev, BO Hofmann, J Gerstoft, A Svejgaard The Lancet 349 (9047), 236-240, 1997 | 505 | 1997 |
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ... Clinical Infectious Diseases 51 (8), 963-972, 2010 | 481 | 2010 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 437 | 2010 |
| Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study N Obel, HF Thomsen, G Kronborg, CS Larsen, PR Hildebrandt, ... Clinical Infectious Diseases 44 (12), 1625-1631, 2007 | 423 | 2007 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 411 | 2014 |
| Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus … M Sulkowski, C Hezode, J Gerstoft, JM Vierling, J Mallolas, S Pol, ... The Lancet 385 (9973), 1087-1097, 2015 | 370 | 2015 |
| Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults E DeJesus, G Herrera, E Teofilo, J Gerstoft, CB Buendia, JD Brand, ... Clinical infectious diseases 39 (7), 1038-1046, 2004 | 351 | 2004 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 308 | 2017 |
| Clinical course of primary HIV infection: consequences for subsequent course of infection. C Pedersen, BO Lindhardt, BL Jensen, E Lauritzen, J Gerstoft, ... British Medical Journal 299 (6692), 154-157, 1989 | 298 | 1989 |
| Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America Antiretroviral Therapy Cohort Collaboration Clinical Infectious Diseases 41 (12), 1772-1782, 2005 | 286 | 2005 |
Christian ErikstrupChair Professor, Chief Physician, Dept. of Clinical Immunology, Aarhus UniversityVerified email at erikstrup.org
